Acute coronary syndrome in the older adults by Dai, Xuming et al.
 Journal of Geriatric Cardiology (2016) 13: 101108 
 ©2016 JGC All rights reserved; www.jgc301.com 
  
http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology 
Cardiovascular Care for Older Adults  Open Access  
 
Acute coronary syndrome in the older adults 
 
Xuming DAI1, Jan Busby-Whitehead2, Karen P Alexander3 
1Division of Cardiology, University of North Carolina at Chapel Hill Chapel Hill, North Carolina, USA 
2Division of Geriatric Medicine, Center for Aging and Health, University of North Carolina at Chapel Hill, North Carolina, USA 
3Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA  
 
J Geriatr Cardiol 2016; 13: 101108. doi:10.11909/j.issn.1671-5411.2016.02.012 
Keywords: Acute coronary syndrome; Aging; Coronary artery disease; Older adults; Risk assessment 
 
 
1  Introduction 
Coronary heart disease remains the leading cause of 
death in the developed world. Advanced age is the single 
strongest risk factor for coronary artery disease (CAD) and 
independent predictor for poor outcomes following an acute 
coronary syndrome (ACS). ACS refers to a spectrum of 
conditions compatible with acute myocardial ischemia 
and/or infarction due to various degrees of reduction in co-
ronary blood flow as a result of plaque rupture/erosion and 
thrombosis formation or supply and demand mismatch. 
Unstable angina and non-ST segment elevation myocardial 
infarction are often continuous and clinically indistinguish-
able, collectively referred as non-ST elevation ACS 
(NSTE-ACS). An abrupt total occlusion of a coronary artery 
causing transmural myocardial ischemia/necrosis and dis-
playing ST segment elevation or new left bundle branch 
block on a12-lead ECG leads to the diagnosis of ST seg-
ment elevation myocardial infarction (STEMI). NSTE-ACS 
and STEMI require acute cardiac care. Professional socie-
ties have established guidelines for high quality contempo-
rary care for ACS patients, i.e., American Heart Associa-
tion/American College of Cardiology guidelines for STEMI 
and NSTE-ACS, European Society of Cardiology guide-
lines for STEMI and NSTE-ACS, and the United Kingdom 
National Institute for Health and Care Excellence guidelines 
for STEMI and NSTE-ACS.[16] Implementation of evi-
dence-based therapies has significantly decreased mortality 
and morbidities of ACS.[3,7,8] However, these advancements 
in ACS management have not equally improved outcomes 
for older adults. Vulnerable older patients continue to be at 
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high risk of poor outcomes, are less likely to receive evi-
dence based care, and have high mortality rates regardless 
of treatments given.[9,10] These disparities and challenges in 
caring for ACS in older adults are well recognized.[1113] 
This review summarizes the increasing burden and persis-
tent unfavorable outcome of ACS in older adults, and dis-
cusses the clinical presentation, diagnosis and strategies for 
medical and invasive therapy. 
2  ACS in older adults 
2.1  Epidemiology 
The exact prevalence and incidence rate of ACS among 
older adults ( 75 years of age) is not known. About 60% of 
hospital admissions for ACS are for patients older than 65 
years of age, and approximately 85% of ACS related deaths 
occur in this age group. Large registries show 32% to 43% 
of NSTE-ACS,[11,14] and about 24%28% of STEMI admis-
sions were for patients aged  75 years.[12] Elderly ACS 
patients were under-represented in clinical trials in which 
subjects older than 75 years of age account for less than 
10%, and older than 85 years account for less than 2% of all 
NSTE-ACS subjects.[15] In both STEMI and NSTE-ACS, 
advanced age independently associates with increased mor-
tality. Mortality is at least three fold higher in patients older 
than 85 years compared with the younger than 65 years of 
age group. The median survival time after a first myocardial 
infarction (MI) is 3.2 years for men and women age  75 
while it is 9.3 years for men and 8.8 years for women aged 
between 65 and 74 years; 17.0 for men and 13.3 for women 
at age 55 to 64 years, respectively.[8] Each 10-year increase 
in age resulted in a 75% increase in hospital mortality in 
ACS patients. Both the Global Registry of Acute Coronary 
Events (GRACE) and UK Myocardial Ischemia National 
Audit Project database revealed ACS of older adults are 
more likely to present as NSTE-ACS instead of STEMI, and 
102 DAI X, et al. ACS in the older adults 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
are more likely to be women, white, and have lower body 
mass indices, higher prevalence of such comorbidities as 
hypertension, heart failure (HF), atrial fibrillation, transient 
Ischemic attack/stroke, anemia and renal deficiency.[16,17] 
As a result of improved prevention and treatment, there is 
a constant trend of steady decline of death rate due to car-
diovascular disease in the USA and other countries. Para-
doxically, the burden of ACS in older adults is expected to 
rise due to (1) expansion of the population age  65 as soci-
ety ages; (2) increased life expectancy; and (3) increased 
population of older adults with history of CAD due to im-
proved therapies. This also means that ACS is an increas-
ingly common presentation in the last stages of life. 
2.2  Pathophysiology 
Atherosclerotic CAD is a result of multi-decade proc-
esses that intertwine with general aging mechanisms.[18] The 
process of atherogenesis includes endothelial injury; lipid 
particle deposition (fatty streak formation); and local cellu-
lar and inflammatory response (early atheroma formation) 
further followed by progression of atheroma with the for-
mation and expansion of necrotic core, fibrous cap, matrix 
accumulation and various degree of plaque instability, in-
tertwined with various degrees of thrombosis formation.  
The “open-artery theory” suggests thrombosis at the site of 
rupture, erosion or fissuring of the atherosclerotic plaque 
leading to STEMI or NSTE-ACS, depending on the degree 
and duration of obstruction.[19] The hallmark of ACS is the 
sudden imbalance between myocardial oxygen consumption 
and demand. This can be due to acute thrombosis and pla-
que rupture, or to increased supply and demand from co-
morbid disease presentations (e.g., tachycardia, hypotension 
or anemia). In older adults, there are more extensive calcifi-
cations of coronary atherosclerosis with more multi-vessel 
and left main disease.[20] These adverse changes increase the 
risk for myocardial injury without new thrombosis. 
3  Clinical presentation and diagnosis 
3.1  Symptoms 
Elderly ACS patients are less likely to present with typi-
cal ischemic chest pain (pressure-like quality, substernal 
location, radiating to jaw, neck, left arm/shoulder and exer-
tional component) compared with younger counterparts. 
Typical angina symptoms predictive of AMI in younger 
patients were less helpful in predicting AMI in the elderly 
population.[21] Autonomic symptoms such as dyspnea, dia-
phoresis, nausea and vomiting, pre-syncope or syncope are 
more common accompaniments to chest discomfort in eld-
erly ACS patients. Symptoms may also be less likely to be 
induced by physical exertion; instead, they are often pre-
cipitated by hemodynamic stressors such as infection or 
dehydration. These may either be type 1 myocardial infarc-
tion if chest symptoms are present, or may also be consid-
ered type 2 MI, if the presentation is more consistent with 
another comorbid condition (e.g., tachycardia, hypoxia from 
pneumonia, chronic lung disease).[22] Other comorbid con-
ditions, such as altered mental status, bleeding episodes, 
falls history, impaired activities of daily living, impaired 
communication skills are also important presenting features 
in guiding ACS care.[23,24] High index of suspicion for ACS, 
along with an appreciation of its context, must be main-
tained in assessing elderly patients to achieve timely diag-
nosis and appropriate treatment. 
3.2  Physical examination 
A careful physical examination focused on mental status, 
vital signs, cardiac murmurs, signs of decomposition of 
heart failure and peripheral artery disease is critical for ac-
curate diagnosis. The elderly patient’s general appearance 
also may provide information about nutritional status and 
frailty. An increased number of comorbid conditions may 
render the older ACS patient less cooperative, and more 
susceptible for hemodynamic instability.  
3.3  Diagnostic testing and differential diagnosis 
3.3.1  Early and serial ECG 
With a high index of suspicion, early acquisition and in-
terpretation of a12-lead ECG, with subsequent serial trac-
ings (e.g., at 15- to 30-min intervals during the initial hour 
of evaluation or recurrence of symptoms) are critical for 
early diagnosis of ACS in the elderly person. Dynamic ST 
segment and T wave changes provide high sensitivity for 
detecting ischemia. ECG interpretation may be challenged 
by pre-existing alterations, pacing rhythm and conduction 
delays. The results of an ECG are less likely to demonstrate 
marked ST-segment deviation. Elderly patients present 
more frequently with NSTE-ACS than STEMI. Due to the 
increased prevalence of left bundle branch block (LBBB) 
with age, older adults with LBBB pose unique challenges, 
as many of these may be previously documented.[11]  
3.3.2  Serial cardiac biomarkers 
Initial and serial cardiac enzymes, with the most sensitive 
biomarker cardiac troponin (cTn) levels, are sensitive and 
specific in diagnosing ACS. Elderly individuals have high 
levels of baseline cTn level: 20% community dwelling older 
adults  70 years old have above 99% cTn level as baseline. 
Careful clinical assessment is essential to separate ACS 
from a variety of acute and chronic conditions also leading 
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to low-level myocardial necrosis (type 2 MI).[25] A bigger 
proportion of the elderly population with ACS has high lev-
els of B-type natriuretic peptide (BNP). Elevated BNP in 
ACS predicts worse outcome.[26,27] Therefore, measurement 
of BNP may provide prognostic information about HF with 
ACS in elders and their risk of mortality. 
3.3.3  Differential diagnosis and diagnostic testing 
Early assessment of cardiac structure and function by 
echocardiography adds diagnostic and prognostic value, and 
guides therapy. A non-ischemic cardiovascular cause of chest 
pain (e.g., aortic dissection, expanding aortic aneurysm, 
pericarditis, pulmonary embolism, severe valvular disease, 
acute decompensation of HF) requires an appropriate im-
aging study to thoroughly evaluate as a possible differential  
Table 1.  Clinical information critical to diagnosis and man-
agement of ACS in the older adults. 
Clinical symptoms for ACS diagnosis 
  Typical symptoms (less predictive for ACS in elderly) 
  Atypical symptoms (more common in elderly) 
  Non-CV acute disease presentation (tachycardia, hypoxia, anemia, hy-
potension) 
  Autonomic symptoms (more common in elderly) 
  Altered mental status (more common in elderly) 
  Exertion-induced symptoms (less common in elderly) 
  Hemodynamic stressor-induced symptoms (more common in elderly) 
History relevant to ACS management 
  Prior MI and intervention history 
  Baseline functional and mental status  
  Baseline quality of life/preferences 
  Expected life expectancy/advanced directive 
  Comorbid conditions (indication for multiple anticoagulants) 
  Frailty/fall risk 
  Bleeding risk 
  Nutritional status 
  Medical compliance/financial concerns 
  Social/family support 
Physical signs relevant to ACS management 
  Mental status 
  Hemodynamic stability 
  Murmurs 
  Signs of decompensated heart failure 
  Peripheral vascular conditions 
  Significant degenerative conditions (scoliosis suggestive for aortic tortu-
osity, etc) 
Laboratory tests 
  Renal function (creatinine clearance calculation) 
  Baseline hemoglobin 
  Cardiac biomarkers 
  Baseline endocrine insufficiency 
  Electrolytes derangement  
ACS: acute coronary syndrome. MI: 
diagnosis. Tachy-arrythmias such as atrial fibrillation are 
common in the older adults who present with ACS symp-
toms requiring ECGs and telemetry. Non-cardiac causes of 
chest pain and abnormal cardiac biomarkers also include 
anemia, renal insufficiency, dehydration, metabolic and 
electrolytes derangements, and infections. To achieve an 
accurate and timely diagnosis requires a focused history and 
physical examination, laboratory tests, and the appropriate 
imaging studies. 
4  Risk stratification 
In general, the greater ischemic risk patients with ACS 
warrant more aggressive strategies, in particular, antithrom-
botic, anticoagulation and revascularization strategies, to 
reduce the risk of major negative clinical outcome (death, 
recurrent ischemia/MI) and often gain the greater benefit 
from these treatments. Prognostic factors predicting higher 
ischemic risk in ACS validated score systems, such as TIMI 
risk score, GRACE score, and TIMI risk index also predict 
higher bleeding risk when receiving aggressive therapies 
(Table 2). Age is one of the most important predictors of 
risk in NSTE-ACS. Patients aged  75 years have at least 
double the mortality rate of those  75 years. As predicted, 
all older adults experiencing ACS (NSTE-ACS and STEMI) 
with elevated cTn with or without ECG changes are high 
risk and who could potentially benefit from aggressive ther-
apy, also have an increased risk of bleeding.[28,29] Frailty 
denoting increased vulnerability and decreased physiologi-
cal reserve in the elderly population, is a strong and inde-
pendent predictor of increased mortality, longer hospital 
stay, and increased risk of bleeding and morbidity in elderly  
Table 2.  Risk factors included in major risk scoring systems 
to predict ischemic and bleeding outcomes in ACS. 
Clinical factors 
Predict-
ing CV 
risk 
Predicting 
bleeding risk 
Predicting long- 
term survival
Advanced age    
Diabetes mellitus   ? 
Male gender   ? 
Renal insufficiency    
Anemia   ? 
Prior CAD, PAD, CVA    
Killip class (HF symptoms)/ 
Hemodynamics 
 
 
 
? 
 
 
ST deviation   ? ? 
Elevated cardiac biomarkers  ?  
Frailty/Functional decline  ?  
Up-ward arrows: increasing risk; down-ward arrows: decreasing risk; ques-
tion marks: undetermined. ACS: acute coronary syndrome; CAD: coronary 
artery disease; CV: cardiovascular: CVA: cerebrovascular accident; HF: 
heart failure; PAD: peripheral arterial disease. 
104 DAI X, et al. ACS in the older adults 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
ACS patients.[30,31] Baseline functional decline in elders is 
also predictive of poor outcome for these patients.[32] Recent 
study found that a positive status suggested by Gold Stan-
dards Framework (GSF) score which incorporated end-stage 
illness criteria and GRACE score cardiovascular criteria, 
independently predicts non-cardiovascular events in ACS 
patients, while GRACE score predicts cardiovascular events 
in this population.[33]    
5  Treatment 
The approach to management of elderly patients with 
ACS should be individualized and balanced based on is-
chemic risks, complication risks, estimated life expectancy, 
co-morbidities, quality of life, patient wishes, and the esti-
mated risks and benefits of revascularization.[11,12] 
5.1  Pharmacotherapy 
The standard of care for patients with ACS in general 
applies to older adults, with the common goals to achieve 
immediate relief of ischemia, prevent further myocardial 
damage, and avoid complications and death. However, 
medication side effects are generally more common in eld-
erly ACS patients; therefore, special attention is required to 
monitor and reduce side effects, particularly in the setting of 
polypharmacy. Adjunctive antiplatelet and/or anticoagulant 
therapies are indicated (Table 3). Bivalirudin may provide 
benefit in reducing bleeding in comparing to unfractionated 
heparin (UFH) plus glycoprotein (GP) IIb/IIIa inhibitor to 
support revascularization. The combination of GP IIb/IIIa 
inhibitors and full dose fibrinolytic medications is associ-
ated with high rates of bleeding and intracranial hemorrhage 
(ICH) in older people. Oxygen support for hypoxemic pa-
tients, anti-angina, antiplatelet, and anticoagulant therapies 
are also generally indicated with special caution for elderly 
patients with ACS (Table 3).  
5.2  Revascularization therapy 
In general, high risk elderly ACS patients benefit from 
invasive revascularization therapy, not only in terms of sur-
vival but also improving quality of life and functional ca-
pacity. Practice guidelines in revascularization therapy for 
STEMI and NSTE-ACS are generally applicable to older 
adults (Table 4). Angiography and percutaneous coronary 
intervention (PCI) are generally safe with high successful 
rates. However, increased risks of stroke and bleeding asso-
ciated with revascularization require careful consideration 
and balance of benefits and risks.[3436] In addition, older 
patients with thrombosis and plaque rupture in coronary 
arteries are more likely to benefit from initial invasive care.  
Table 3.  Pharmacotherapy for ACS in older adults. 
Agents Special comment in older adult 
Oral antiplatelet agents 
Aspirin 
P2Y12 receptor inhibitors 
Clodiogrel 
Prasugrel 
Ticagrelor 
 
 
Beneficial: indicated, well tolerated 
 
Beneficial: indicated, well tolerated 
Relatively contra-indicated in age ≥ 75 years of age; body weight < 60 kg; and history of CVA/TIA 
More potent than clopidogrel, may be better outcome, without increased risk of bleeding; twice daily and cost may 
be troublesome for older adults 
GP IIb/IIIa inhibitor (GPI) Beneficial in conjunction with PCI and heparin in elderly with increased risk of bleeding requiring transfusion 
Anti-coagulants 
UFH 
Enoxaparin 
Fondaparinux 
Bivalirudin 
Factor Xa inhibitors 
 
Beneficial: may add GPI with PCI 
May be used prior to PCI; no bolus with reduced dosage for  75 years of age; increased bleeding risk 
Not recommended as sole anticoagulant for PCI due to catheter thrombosis; increased bleeding risk in elderly 
Mono-agent for PCI has comparable efficacy as UFH+GPI, but reduces bleeding risk than UFH+GPI in elderly ACS
Rivaroxaban and Apixaban (only rivaroxaban approved for secondary prevention) 
Fibrinolytics 
 
Only for STEMI when expected to delay > 120 min from FMC to FDA; advanced age increases risk of intracranial 
hemorrhage; half-dose for  75 year-old; Fibrin-specific agents have lower risk of bleeding in elderly 
Nitroglycerin Ameliorates symptoms, reduces LV preload, increases coronary flow. Be cautious of hypotension 
Beta-blockers 
 
Oral beta-blockers benefit elderly more than younger adults 
IV beta-blockers are harmful in ACS with HF presentation 
ACEi/ARB Beneficial with reduced EF – caution if CKD for creatinine and potassium level changes 
Statins 
 
Greater beneficial in elderly than younger adults, side-effects are more common as well, moderate intensity maybe 
as good as high intensity statin. Cautions are required – Guidelines now for moderate intensity statin age  years 
ACEi: angiotensin converting enzyme inhibitors; ACS: acute coronary syndrome; ARB: angiotensin receptor blockers; CKD: chronic kidney disease; CVA: 
cerebrovascular accident; EF: ejection fraction; FDA: first device activation; FMC: first medical contact; GPI: glycoprotein IIb/IIIa inhibitors; LV: left ventricle; 
PCI: percutaneous coronary intervention; STEMI: segment elevation myocardial infarction; TIA: transient ischemic attack; UFH: unfractionated heparin. 
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Table 4.  Statements in major guidelines relevant to management of ACS in the older adults. 
ACS Guideline statements 
Class, level 
of evidence 
Guidelines 
A high index of suspicion for MI must be maintained in women, diabetics, and elderly patients with atypical symp-
toms 
I, B 
STEMI 
Special attention must be given to proper dosing of antithrombotics in elderly and renal failure patients I, B 
2011 ESC 
Guidelines for 
STEMI 
Because of the frequent atypical presentation, elderly patients (> 75 years) should be investigated for NSTE-ACS at 
low level of suspicion 
I, C 
Treatment decisions in the elderly (> 75 years) should be made in the context of estimated life expectancy, 
co-morbidities, quality of life, and patient wishes and preferences 
I, C 
Choice and dosage of antithrombotic drugs should be tailored in elderly patients to prevent the occurrence of ad-
verse effects 
I, C 
Elderly patients should be considered for an early invasive strategy with the option of possible revascularization, 
after careful weighing up of the risks and benefits 
IIa, B 
2011 ESC 
Guidelines for 
NSTE-ACS
Older patients with NSTE-ACS should be treated with GDMT, an early invasive strategy, and revascularization as 
appropriate 
I, A 
Pharmacotherapy in older patients with NSTE-ACS should be individualized and dose adjusted by weight and/or 
CrCl to reduce adverse events caused by age-related changes in pharmacokinetics/dynamics, volume of distribu-
tion, comorbidities, drug interactions, and increased drug sensitivity 
I, A 
Management decisions for older patients with NSTE-ACS should be patient centered, and consider patient prefer-
ences/goals, comorbidities, functional and cognitive status, and life expectancy 
I, B 
Bivalirudin, rather than a GPIIb/IIIa inhibitor plus UFH, is reasonable in older patients with NSTE-ACS, both 
initially and at PCI, given similar efficacy but less bleeding risk 
IIa, B 
NSTE-ACS 
It is reasonable to choose CABG over PCI in older patients with NSTE-ACS who are appropriate candidates, par-
ticularly those with diabetes mellitus or complex 3-vessel CAD (e.g., SYNTAX score > 22), with or without in-
volvement of the proximal LAD artery, to reduce CVD events and readmission and to improve survival 
IIa, B 
2014 
AHA/ACC 
guideline for 
NSTE-ACS
ACS: acute coronary syndrome; CABG: coronary artery bypass grafting; CrCl: creatinine clearance; CVD: cardiovascular disease; GDMT: guideline-directed 
medical therapy; GP: glycoprotein; LAD: left anterior descending; NSTE: non-ST elevation; PCI: percutaneous coronary intervention; STEMI: ST elevation 
myocardial infarction; UFH: unfractionated heparin. 
 
However, data to guide this invasive risk stratification in 
older adults is limited, so the treatment decision remains in 
the realm of clinical judgment. 
5.2.1  STEMI 
Timely reperfusion is the cornerstone in caring patients 
with STEMI and is applicable to elderly patient population. 
Even the very elderly STEMI patients have reasonable 
post-MI outcomes when treated aggressively with reperfu-
sion therapy. In all age groups, primary PCI with stent 
placement is the preferred strategy over thrombolysis, when 
primary PCI is feasible and timely. In high risk elderly 
STEMI patients, primary PCI is generally safe as well. It 
results in even greater survival benefit for older compared 
with younger counterparts, reduces re-infarction and tar-
get-vessel revascularization, and is associated with less ICH. 
Emergent primary PCI may also provide survival benefit in 
elderly STEMI with cardiogenic shock.[37] An integrated 
regional STEMI transfer program is applicable to elderly 
patients, and proven to lessen age-related treatment dispari-
ties and  to improve outcome.[38] In comparison with pla-
cebo, fibrinolytic therapy reduces STEMI mortality in elders 
up to the age of 85 years.[39] Today, in elderly STEMI pa-
tients, fibrinolytic therapy should be only used in confirmed 
STEMI, presenting ≤ 12 h after symptom onset and ex-
pected to have system delay ≥ 120 min before first-device 
activation (FDA) and without contraindications.[34,35,40,41] 
Elderly STEMI patients receiving fibrinolytic therapy 
should be immediately transferred to a PCI center with con-
tinued assessment of reperfusion, and early angiography and 
revascularization.[42,43] In older adults, coronary artery by-
pass grafting (CABG) has a limited role in the acute phase 
of STEMI with excess mortality risk, unless in the settings 
of failed PCI, coronary anatomy not amenable to PCI, or 
requiring surgical repair of mechanic complications [ven-
tricular septal defect (VSD), papillary muscle rupture, 
free-wall rupture].  
5.2.2  NSTE-ACS 
Older adults with NSTE-ACS are generally at higher 
ischemic risk than younger groups. An early invasive strat-
egy compared with an ischemia-guided strategy was found 
to have more benefit in the elderly than younger patients, 
unless there were extensive and prohibitive comorbidities 
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(e.g. hepatic, renal, pulmonary failure, cancer etc.).[34,44,45] 
The advancement of equipment and technique has made 
PCI safer for even very elderly patients (≥ 90 years of age) 
with high success rates and declining major bleeding risk. 
Although the highest risk reduction in death/MI with an 
early invasive strategy occurred in those ≥ 75 years of age, 
this strategy was associated significantly increased bleeding 
risk. Older patients with NSTE-ACS, and diabetes mellitus 
have a greater survival advantage with CABG as revascu-
larization modalities. However, operative mortality rates 
and risk of complications (i.e., stroke) for CAGB in elderly 
patients were substantial (up to 8% at ≥ 80 years of age). 
Prolonged hospitalization and post-surgery recovery in older 
persons were also significant.  
5.3  On-going care 
The elderly ACS patients require close inpatient moni-
toring for potential complications from ischemic events, 
invasive procedures and side effects from medical treatment, 
in particular for the risk of bleeding with antiplatelet agents 
and anticoagulants, and also for hypotension, bradycardia, 
and renal failure. Acute ACS hospitalization of older adults 
often provides the healthcare system an opportunity to 
re-assess the patients’ social status and supportive networks, 
re-establish aggressive risk modification strategies (smoking 
cessation, treating hypertension, hyperlipidemia, diabetes 
mellitus, and physical inactivity, etc), secondary prevention 
and provide guideline directed medical therapy.  
6  Post-ACS care for the older adults  
Older adults are susceptible to experience complications 
from ACS. In the acute phase, these complications include 
but are not limited to (1) ischemia related complications 
(HF due to pump failure; post-MI pericarditis; arrhythmia 
(both ventricular and atrial arrhythmia, conduction system 
malfunctions); mechanical complications from ischemia, i.e., 
papillary muscle rupture, VSD, free wall rupture ); (2) pro-
cedural complications (access site bleeding/hematoma, re-
troperitoneal bleeding, stroke, pericardial effusion); (3) 
bleeding due to anti-platelet therapy and anemia; (4) renal 
insufficiency; (5) hypotension due to excessive medications; 
and (6) adverse effects from new medications. Post ACS, 
elderly patients have a high risk of re-hospitalization and 
death both from cardiovascular and non-cardiovascular eti-
ologies. There is a 50% increased mortality risk per 10-year 
increase in age starting from 65 years of age.[46]   
6.1  Patient education and social support 
Elderly patients suffering from ACS are particularly vul-
nerable. Due to comorbid conditions, polypharmacy, frailty 
and often impaired communication skills and cognitive func-
tion, a comprehensive discharge planning process involving 
patient, family and advocates is essential and often challeng-
ing. Failure to understand and comply with a plan of care 
contributes to high rate of ACS re-admission rates and poor 
outcomes. The post-hospitalization care plan should include 
(1) detailed medication lists and instructions; (2) clear follow- 
up arrangement; (3) dietary instructions; (4) physical activ-
ity instructions; (5) reaction plan for adverse effects from 
medications and interventions; and (6) cardiac rehabilitation. 
6.2  Secondary prevention and lifestyle modification 
Aggressive lifestyle modification (smoking cessation, 
weight control, dietary intervention, etc) and pharmacologi-
cal secondary prevention (tighter blood pressure and serum 
glucose control, statin therapy, etc) are indicated for older 
adults treated for ACS. Close collaboration among cardi-
ologists, general practitioner, patient's rehabilitation special-
ists, pharmacists, dieticians, and patients and caregivers are 
crucial for the ongoing care.  
6.3  Cardiac rehabilitation and exercise 
Comprehensive cardiac rehabilitation programs provide 
patient education, identify and monitor risk factors, address 
lifestyle modification; provide psychosocial support and 
enhance exercise training for patients with ACS.[47] These 
programs were robustly tested and proven to be beneficial to 
all spectrums of age group ACS patients and endorsed by 
societal guidelines and healthcare administration. Exercise 
therapy improves functional capacity, cardiorespiratory fit-
ness, and perception of well-being, as well as reduces car-
diac event rate. Each step of increase in peak exercise ca-
pacity is associated with a reduction in all-cause mortality 
risk in all age groups, including elderly patients. Elderly 
ACS patients should be encouraged to participate in cardiac 
rehabilitation. However, low rate of referral and participa-
tion in cardiac rehabilitation by eligible elderly ACS pa-
tients were repeatedly reported. Healthcare providers must 
eliminate barriers to referrals and enrollment, and facilitate 
participation and monitor progress.  
7  Opportunities for future research and clini-
cal pearls 
For research, there are urgent needs to: (1) Establish ef-
fective approaches to improve public awareness of symp-
toms and signs of ACS to minimize patient delays in pres-
entation; (2) Advocate the expansion of enrollments of older 
adults in ACS clinical trials; (3) Develop or optimize risk 
DAI X, et al. ACS in the older adults 107 
  
http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology  
stratification algorithm incorporating frailty and functional 
data for ischemia outcomes and complication risks and their 
efficacy in guiding clinical decision making; (3) Study indi-
vidualized, targeted strategies for coronary revascularization 
that achieve optimized goal of care for elderly ACS patients; 
(4) Study new safety, efficacy and optimal duration of novel 
P2Y12 antagonists in older adults; (5) Optimize cardiac 
rehabilitation programs for elderly ACS patients.  
The clinical pearls are: (1) Older adults make up an in-
creasingly large proportion of ACS patients. However, there 
are significant disparities in collecting clinical evidence and 
delivery of evidence-based effective therapy to these pa-
tients compared with their younger counterparts. (2) Type 2 
MI is increasingly common with highly sensitive troponin 
assays. Judgment regarding coronary risk and revasculariza-
tion is warranted, and initial strategy should focus on treat-
ment of presenting non-cardiac conditions with monitoring 
for CAD complications. (3) High risk elderly ACS patients 
may derive more benefit from aggressive antithrombotic 
therapy and invasive revascularization, but also carry higher 
risks of complications, such as bleeding and stroke. (4) Op-
timized approach requires careful considerations of the in-
dividual patient’s ischemic risk, comorbidities, risk of com-
plications, frailty, cognitive function, life expectancy and 
advanced directive (patient’s wish). (5) All older adults who 
survived from ACS should be encouraged and referred for 
cardiac rehabilitation. Exercise training improves long term 
survival and well-being of ACS patients. 
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